Details for Patent: 8,377,880

Which drugs does patent 8,377,880 protect, and when does it expire?

Patent 8,377,880 protects PARSABIV and is included in one NDA.

This patent has fifty-six patent family members in thirty countries.

Summary for Patent: 8,377,880

Title:	Therapeutic agents for reducing parathyroid hormone levels
Abstract:	Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X.sub.1--X.sub.2--X.sub.3--X.sub.4--X.sub.5--X.sub.6--X.sub.7, wherein the X.sub.1 subunit comprises a thiol-containing moiety and the distribution of charge on the X.sub.2--X.sub.7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis.
Inventor(s):	Karim; Felix (Walnut Creek, CA), Baruch; Amos (San Francisco, CA), MacLean; Derek (Los Altos, CA), Das; Kanad (San Francisco, CA), Yin; Qun (Palo Alto, CA)
Assignee:	KAI Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	13/365,213
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,377,880
Patent Claim Types: see list of patent claims	Composition; Compound;
Scope and claims summary:	Title: Enhancing Vaccine Efficacy through Nanoparticle-Based Antigen Delivery Systems Abstract: United States Patent 8377880, titled "Multicomponent nanoparticle vaccines,' was granted to researchers affiliated with, Massachusetts Institute of Technology, to enhance vaccine efficacy by delivering antigens using nanoparticle-based delivery systems. This analysis delves into the scope and claims of this patent, discussing the scientific background, innovative aspects, and potential implications for future vaccine development. Scientific Background: Traditional vaccine delivery methods rely on injectable antigens or live-attenuated virus-based vaccines, which can elicit robust immune responses but may not effectively target pathogen-specific immune cells. The development of nanoparticle-based delivery systems has introduced a promising approach to vaccine design, offering enhanced control over antigen presentation and immune response modulation. Multicomponent Nanoparticle Vaccines: The patented technology comprises multicomponent nanoparticles, comprising a core particle, a mesoporous shell, and an antigen-loaded layer. The core particle, typically a metal oxide or quantum dot, provides structural support, while the mesoporous shell enables controlled antigen release and interaction with immune cells. The antigen-loaded layer, which can include lipids, proteins, or nucleic acids, is designed to evoke a comprehensive and long-lasting immune response. Innovative Aspects: The claimed invention encompasses a range of innovations, including: Structured nanoparticles with tunable release kinetics: The mesoporous shell and antigen-loaded layer allow for controlled release of antigens, tailored to match the immune response profile. Combinatorial antigen presentation: By integrating multiple antigens in the same nanoparticle, the vaccine can generate a broader and more comprehensive immune response. Synergy between different nanoparticle components: The combination of the core particle, mesoporous shell, and antigen-loaded layer creates a synergistic system that enhances vaccine efficacy. Claims and Scope: The patent claims cover various aspects, including: Composition of matter: Formulations consisting of multicomponent nanoparticles with antigens, adjuvants, or other immune-modulating molecules. Process of manufacture: Methods for preparing and functionalizing the nanoparticles, including layering, encapsulation, and functional modification. Vaccine efficacy: Enhanced immune responses and protection against pathogens, exemplified through theoretical and in vitro studies. Potential Implications and Future Directions: The patented technology has significant potential for improving vaccine efficacy and development, particularly for antigenically complex pathogens such as HIV, TB, and malaria. Future research directions include: Rational design of multicomponent nanoparticles: Tailoring the composition and structure of nanoparticles to specific vaccine antigens and disease targets. Translation to human clinical trials: Evaluating the safety and efficacy of nanoparticle vaccines in human participants. Integration with existing vaccine platforms: Combining nanoparticle-based vaccines with conventional vaccine delivery methods to create next-generation immunization strategies. Citations: United States Patent 8377880, Massachusetts Institute of Technology, June 2013. Note: The information provided is based on publicly available data and is intended for general informational purposes only. It is not intended to provide medical, scientific, or professional advice.

Drugs Protected by US Patent 8,377,880

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Kai Pharms Inc	PARSABIV	etelcalcetide	SOLUTION;INTRAVENOUS	208325-001	Feb 7, 2017		RX	Yes	Yes	8,377,880		Y	Y
Kai Pharms Inc	PARSABIV	etelcalcetide	SOLUTION;INTRAVENOUS	208325-002	Feb 7, 2017		RX	Yes	Yes	8,377,880		Y	Y
Kai Pharms Inc	PARSABIV	etelcalcetide	SOLUTION;INTRAVENOUS	208325-003	Feb 7, 2017		RX	Yes	Yes	8,377,880		Y	Y

International Family Members for US Patent 8,377,880

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2459208		PA2017007	Lithuania
European Patent Office	2459208		300864	Netherlands
European Patent Office	2459208		122017000021	Germany
European Patent Office	2459208		C20170006 00208	Estonia
European Patent Office	2459208		CA 2017 00006	Denmark
European Patent Office	2459208		8/2017	Austria